ArticleJTO clinical and research reports2026

Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma.

Peey-Sei Kok et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.